top of page

SPONSORS

​

Biomedcode, a Contract Research Organization (CRO) specializing in Preclinical Testing, is a silver sponsor at our conference. With a rich history of groundbreaking research, they've developed unique humanized transgenic mouse models that faithfully replicate various human diseases, offering a platform for the efficient evaluation of human therapeutics.

Their extensive portfolio includes disease models for acute inflammation, rheumatoid arthritis, and more. Biomedcode's preclinical services are tailored to meet individual needs, characterized by standardized procedures and exceptional customer-oriented support.

Their team of highly skilled scientists and cutting-edge laboratory facilities reinforce their lead in the preclinical testing field, while a dynamic Research & Development program continually innovates humanized animal disease models.

Biomedcode plays a major role in the world of biomedicine, and we are delighted to have them as a sponsor at our conference.

​

You can visit Biomedcode :   biomedcode.com

DEMO S.A. Pharmaceutical Industry is an industrial and commercial organization established in 1965 and active in the production and sales of pharmaceutical products.

During the past years, DEMO S.A. has achieved a significant growth in all its business segments. This growth has enabled us to achieve results that are a testament to the quality and dedication of our employees.

  • Ranked #1 in production facilities for injectables in Greece

  • Ranked #1 in hospital sales (in terms of sold units) and exports of branded products in Greece

  • Within the Top 100 Greek industries

  • Ranked #1 company in private funds invested in Greece

  • Ranked #1 in new jobs creation in Greece

  • Within the Top 200 Companies in new jobs creation in the European Union

  • Official Supplier of the United Nations

  • Official Supplier of UNICEF

  • Official Supplier of World Health Organization

  • Official Supplier of Medicines Sans Frontiers

  • Official Supplier of International Committee of the Red Cross  

 

You can visit Demo :   www.demo.gr

Τhe Pharmaceutical Company COOPER S.A. was founded in 1936 and has had a continued presence in the pharmaceutical Greek pharmaceutical market up to the present day.

This presence has been a notable one, making an indelible mark with both its innovative techniques in the production of parenteral solutions, injectable antibiotics, classic and unique Hospital drugs and its well known tried and tested full range of ophthalmic products, and its equally important partnerships with recognized Companies abroad.

It has faced all the difficulties it has encountered on its path with great success, as indicated by its ongoing presence over the years.

Today the fully Greek-owned company, established with a new equity and administrative structure in 2006, looks forward to the future with optimism, ready to face the challenges of the present. Its aim is to establish itself as a dynamic pharmaceutical production unit, whilst developing partnerships with major companies abroad in the fields of both pharmaceutical medicine and medical devices.

Flexibility – Speed – Adaptability. Incorporation of both new technologies and new management methods, the integration of quality standards and quality control systems in its production processes and other organisational activities, as well as maximized utilization of the substantial capital funds available to it combined with its human resource development, all lead towards growth and its establishment as a major force in its field.

The commitment of Management to the Company’s dynamic growth and implementation of its quality objectives are the cornerstone of progress today and tomorrow. The strategic course which COOPER SA has set is based on effective service of the needs of the Medical community and Greek patient care.

Visit COOPER : koper.gr

The Panhellenic Association of Pharmaceutical Companies (PEF) is the institutional body representing the Greek pharmaceutical industry, a large and dynamic sector of strategic importance for the National Economy. Greek pharmaceutical companies develop expertise and primarily produce generic drugs (essentially equivalent to branded generics), adhering strictly to quality assurance (QA) standards and good manufacturing practices (GMP) regulations.

Established with the aim of contributing to the creation of favorable operating conditions in the Greek pharmaceutical market and its development in the international environment, the PEF seeks:

  1. The advancement of pharmaceutical science for the benefit of citizen healthcare and the improvement of daily quality of life.

  2. The complete coverage of the Greek pharmaceutical market with high-quality drugs at reasonable costs.

  3. The healthy growth of the pharmaceutical market.

  4. The existence of modern and competitive Greek production units so that the Greek pharmaceutical market is not solely dependent on imported drugs.

​

Visit Pef : www.pef.gr

7.png

Servier, a Global Pharmaceutical Group

Servier is an international pharmaceutical group governed by a foundation, founded with the mission to serve health and aspire to have a significant social impact for patients and a sustainable world. With its unique governance model, it is able to fully fulfill its purpose with a long-term vision: to be committed to therapeutic progress to meet the needs of patients. The 21,400 employees of the Group are dedicated to its purpose, which serves as a daily source of inspiration.

As a leader in cardiology, the Servier Group's ambition is to be a recognized, focused, and innovative player in oncology, focusing on challenging-to-treat cancers. For this reason, the Group invests over 50% of its Research & Development budget in developing targeted and innovative therapies in oncology. Neuroscience and inflammatory diseases are future growth drivers. In these therapeutic categories, Servier focuses on a limited number of diseases where the precise patient profile enables precision medicine with the administration of targeted therapies.

In order to provide access to the maximum possible healthcare at a lower cost, the Group also offers a range of quality generic drugs covering most pathological conditions. It relies on strong companies based in France, Eastern Europe, Brazil, and Nigeria.

In all these areas, the Group incorporates the patient's voice at every stage of the life cycle of a drug.

Headquartered in France, Servier has a strong geographical presence in over 150 countries and a turnover of €4.9 billion in 2022.

​

Visit Servier : servier.gr

bottom of page